Dividends/Fixed Income

Junk Bonds Say It’s Too Early to Fret

Ivan Martchev | |

It would be very unusual for the stock market to weaken further in a good earnings environment in the seasonally strong time of the year.

Mortgage Loan Applications: How the Economy Impacts You

Richard Parker | |

The best time to apply for a mortgage or mortgage refinance is based on these economic indicators.

​Here’s Where the Next Financial Crisis Begins

Harry Dent | |

The trigger this time looks to be corporate loan failures in emerging countries, starting with Turkey and the worst, Venezuela.

No Time for a Big Bond Bear

Ivan Martchev | |

While the 10-year Treasury note yield closed Friday at a multi-year high of 3.22%, launching talk of a bear market in bonds, I have to remind readers of this column that we have been there before.

An Important Year for Bond Investors | |

After ten long years the markets are now offering yields on ultra-safe one year treasuries above the inflation rate, as measured by Personal Consumption Expenditures (PCE).

Significant Emerging Markets Contagion is Very Much Possible

Ivan Martchev | |

Another week and another all-time low for the Argentine peso, which registered its first weekly close above 40 per dollar, or 41.28 to be exact.

Junk Bond Prices Are Still Too Expensive

Ivan Illán | |

Junk bonds have a long way to go before offering more attractive yields to compensate for their inherent credit risk.

Are Dividends Telling Us Something?

Lance Roberts | |

Since 2009, due to the Federal Reserve’s suppression of interest rates, investors have piled into dividend yielding equities, regardless of fundamentals, due to the belief “there is no alternative.”

The Asia Pacific Fund: Striving for Growth and Value

Derek Hansen | |

As U.S. stock markets rally to new records, investors are increasingly looking to Asia for new growth opportunities.

Dividend Investments: Brookfield Global Listed Infrastructure Income Fund Offers Elevated Return Potential


One sector that should be considered by value-oriented investors is in closed-end funds, which often trade at attractive discounts relative to net asset value.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.


Truth on Trial: Implications for Communicators – Part III

Truth on Trial” is just one of a series of forums put on by the Schar School of Policy & Government, whose panelists are among the most influential legal, communications,…

Learn more